Cybin Inc., a Phase 3 clinical-stage neuropsychiatry company, announced the closing of its registered direct offering for gross proceeds of approximately US$175 million. The financing included 22,277,750 common shares and 4,605,500 pre-funded warrants priced at US$6.51 each, with participation from leading investors including Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, and Adage Capital Partners. Each unit includes 0.35 of a warrant exercisable at US$8.14 per share before June 30, 2027, or earlier under specified conditions.
The substantial capital infusion positions Cybin to accelerate development of its novel psychedelic-based therapeutics at a critical juncture for the mental health treatment landscape. With mental health disorders affecting millions globally and current treatments often providing inadequate relief, the company's approach represents a potential paradigm shift in neuropsychiatry. Jefferies, TD Cowen, and Cantor acted as joint lead placement agents, with Bloom Burton Securities Inc. serving as placement agent for the offering.
Cybin is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder. The compound has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, recognizing its potential to demonstrate substantial improvement over existing therapies. The company is also advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. Additional information about Cybin's developments is available at https://ibn.fm/CYBN.
The $175 million financing represents one of the largest recent capital raises in the psychedelic medicine sector, signaling growing institutional confidence in the therapeutic potential of psychedelic compounds. This funding milestone comes as the mental health treatment field faces increasing pressure to develop more effective options, with traditional antidepressants and anxiolytics often providing limited efficacy and significant side effects for many patients. The investment from established healthcare and biotech-focused funds like Venrock Healthcare Capital Partners and OrbiMed validates the commercial potential of psychedelic-assisted therapies.
For the broader psychedelic industry, Cybin's successful capital raise demonstrates that well-structured clinical development programs can attract substantial institutional investment, potentially paving the way for additional funding opportunities across the sector. The company's operational presence in Canada, the United States, the United Kingdom, and Ireland positions it to navigate diverse regulatory environments as psychedelic medicine continues to gain acceptance globally. The funding will support the advancement of Cybin's research pipeline of investigational, 5-HT-receptor focused compounds, potentially accelerating the timeline for bringing novel mental health treatments to market.
